Origin Genomics aims to prove the potential benefits of its technology for editing disease-causing genes in human embryos ...
The average one-year price target for 10x Genomics (NASDAQGS:TXG) (LSE:0A88) has been revised to $60.62 / share. This is an increase of 13.66% from the prior estimate of $53.33 dated September 11, ...
Genomics Inc. stocks have been trading up by 5.34 percent after upbeat coverage on its expanding single-cell sequencing ...
TXG begins Atera shipments as orders top 40 systems, highlighting strong early demand and broad research interest in its ...
PRNewswire/ -- (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, ...
StockStory.org on MSN
10x Genomics (TXG) stock is up, what you need to know
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.8% in the afternoon session after Argus analyst ...
Major discoveries, including the role of DNA, the biological basis of psychology, and the human genome, missed out on science ...
Automation, enzymatic synthesis and integrated services can cut costs, speed turnaround and capture demand from RNA therapeutics, NGS and CRISPR.Dublin, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ...
Lynne Stewart Trobaugh died in January 2026 after a 2.5-year battle with ovarian cancer. Her family is choosing to channel ...
Researchers at Baylor College of Medicine, the Duncan Neurological Research Institute (Duncan NRI) at Texas Children's ...
Introduced in April of this year, Atera brings together whole transcriptome analysis, sub-cellular resolution, single cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results